卡维地洛对重症充血性心力衰竭患者的临床疗效评价

Efficacy evaluation of carvedilol in the treatment of severe congestive heart failure

目的 评价第三代 β受体阻滞剂卡维地洛对重症充血性心力衰竭患者的临床疗效。 方法 将 3 3例重症充血性心力衰竭患者随机分为 2组 ,卡维地洛组 17例 ,应用卡维地洛及心衰常规治疗 ,卡维地洛起始剂量为 2 .5～ 5mg ,Bid ,如患者能耐受 ,在 2～ 4周内逐渐将剂量增加至 2 0mg ,Bid ,维持治疗 3个月。对照组 16例 ,用心衰常规治疗。 结果 卡维地洛组能显著改善重症充血性心力衰竭患者的左、右室心功能 ,使心率、心搏量、左室射血分数、肺动脉收缩压 (右室后负荷 )与组内治疗前比较差异有显著意义 ;心搏量、心排血量、左室射血分数与对照组治疗后比较差异有显著意义。卡维地洛组未见明显不良反应。结论 卡维地洛治疗重症充血性心力衰竭是安全。

OBJECTIVE To evaluate the efficacy of carvedilol (third generation β receptor blocker) in the treatment of severe congestive heart failure. METHOD 33 cases of severe congestive heart failure were divided into 2 groups randomly. The patients of carvedilol groups ( n =17) were treated with carvedilol and routine therapy of heart failure. Carvedilol began with 2.5～5mg Bid and increased successively to 20mg Bid within the permitting dosage after 2～4 weeks, the whole course lasted for 3 months. The control groups ( n =16) only received routiue therapy of heart failure. RESULTS After treatment, the ventricular function of carvedilol group improved significantly, according to heart rate, cardiac stroke volume, ejection fraction and systolic pressure of pulmonary artery. And in carvedilol group, the cardiac stroke, cardiac output, ejection fraction and systolic pressure of pulmonary artery were significantly different from those of control group.CONCLUSION Carvedilol is effcetive and safe in the treatment of severe congestive heart failure.